MSH2 and thymus lymphoma: All recipients receiving MSH2-/- BM cells developed thymic lymphomas within 3 to 4 months, while no lymphomas were observed in recipients of MSH2-/- thymocytes or splenocytes up to 9 months (Fig 1A).